Endogenous knockdown of survivin improves chemotherapeutic response in ALL models

First human dose study evaluating safety and pharmacokinetics of LY2181308, an antisense oligonucleotide designed to inhibit survivin

(2017) D. C. Talbot et al.   JOURNAL OF CLINICAL ONCOLOGY

Down-Modulation of Survivin Expression and Inhibition of Tumor Growth In Vivo by EZN-3042, A Locked Nucleic Acid Antisense Oligonucleotide

(2010) Puja Sapra et al.   NUCLEOSIDES NUCLEOTIDES & NUCLEIC ACIDS

Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents

(2009) C. A. Stein et al.   NUCLEIC ACIDS RESEARCH

mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia

(2008) D. T. Teachey et al.   BLOOD

Phase I and Pharmacokinetic Study of YM155, a Small-Molecule Inhibitor of Survivin

(2008) Anthony W. Tolcher et al.   JOURNAL OF CLINICAL ONCOLOGY

SPC3042: a proapoptotic survivin inhibitor

(2008) J. B. Hansen et al.   MOLECULAR CANCER THERAPEUTICS

Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells

(2008) N. Zhu et al.   MOLECULAR CANCER THERAPEUTICS

Interplay among BRCA1, SIRT1, and Survivin during BRCA1-Associated Tumorigenesis

(2008) Rui-Hong Wang et al.   MOLECULAR CELL